TruScreen Group Limited Share Price
Current Share Price data for TruScreen Group Limited (NZX:TRU ASX:TRU)
TruScreen Group Financial Reports
FY23 Annual Report
30.6.2023
2023 Annual Report
Annual Report for the year ended March 2023
FY23 Half Year Report
29.11.2022
2023 Half Year Report
Half Year Report for the period ended September 2022
FY22 Annual Report
30.6.2022
2022 Annual Report
Annual Report for the year ended March 2022
FY22 Half Year Report
29.11.2021
2022 Half Year Report
Half Year Report for the period ended September 2021
FY21 Annual Report
30.6.2021
2021 Annual Report
Annual Report for the year ended March 2021
FY21 Half Year Report
4.11.2020
2021 Half Year Report
Half Year Report for the Half-Year ended September 2020
FY20 Annual Report
29.6.2020
2020 Annual Report
Annual Report for the year ended March 2020
FY20 Half Year Report
28.11.2019
2020 Half Year Report
Half Year Report for the Half-Year ended September 2019
FY19 Annual Report
1.7.2019
2019 Annual Report
Annual Report for the year ended March 2019
FY19 Half Year Report
14.12.2018
2019 Half Year Report
Half Year Report for the Half-Year ended September 2018
FY18 Annual Report
31.7.2018
2018 Annual Report
Annual Report for the year ended March 2018
2018 Half Year Report
14.12.2018
2018 Half Year Report
Report for the Half-Year ended September 2017
FY17 Annual Report
31.7.2017
2017 Annual Report
Annual Report for the year ended March 20217
FY17 Half Year Report
14.12.2016
2017 Half Year Report
Report for the Half-Year ended September 2016
The TruScreen Group manufactures and owns all rights to the TruScreen Cervical Cancer Screening Device. The system comprises a medical device and process designed to detect the presence in real time of pre-cancerous and cancerous tissue on the cervix.
Company InformationCervical cancer is the fourth most common cancer in women
In low- and middle-income countries (LMICs) cervical cancer is the second most common form of cancer among women.
5 facts you may not know about cervical cancer
